Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Bayonne – page 2

196 clinical trials in Bayonne, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Bayonne at a glance
196
clinical trials
  • Paediatric trials0
  • Research sites2
Type of trial
Recruitment status
Quick filters

196 trials in Bayonne

Open in trial search

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

Endometrial cancer+2

Recruiting

A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Genmab A/S

Acute myeloid leukaemia

Recruiting

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Syndax Pharmaceuticals Inc.

Acute myeloid leukaemia

Recruiting

A Study Comparing Two Treatment Schedules of Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Suitable for Intensive Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Azacitidine
  • Sponsor:Institut Gustave Roussy

Crohn's disease

Recruiting

Study of icotrokinra for adults with moderately to severely active Crohn's disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Colitis ulcerative

Recruiting

Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Pancreatic carcinoma metastatic+1

Recruiting

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Renal cell carcinoma

Recruiting

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Gastrooesophageal cancer+1

Recruiting

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fruquintinib
  • Sponsor:Fondation Franc.Cancerologie Digestive

Adenocarcinoma pancreas

Recruiting

Study of Gemcitabine with Paclitaxel versus Standard Chemotherapy Combination for Patients with Borderline Resectable Pancreatic Cancer Based on Gene Analysis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Fondation Franc.Cancerologie Digestive

Colorectal cancer metastatic

Recruiting

Study of FOLFOX or FOLFIRI chemotherapy with fruquintinib or bevacizumab as second-line treatment for patients with metastatic colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Bayonne

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking research focusing on multiple myeloma and various types of lymphoma, evaluating novel therapeutic combinations and maintenance strategies.

  • Multiple Myeloma Treatment Innovations
  • Diffuse Large B-Cell Lymphoma Therapies
  • Post-Transplant Maintenance Protocols

Studies are exploring combinations of elranatamab, lenalidomide, and other targeted therapies to improve patient outcomes.

02 Solid Tumors

Comprehensive research into various types of solid cancers, including breast, lung, and colorectal cancers, testing innovative treatment approaches.

  • Advanced Breast Cancer Treatments
  • Non-Small Cell Lung Cancer Therapies
  • Colorectal Cancer Interventions

Trials are evaluating targeted therapies and immunotherapy combinations for better treatment outcomes.

03 Autoimmune Conditions

Innovative studies addressing multiple sclerosis and inflammatory conditions, focusing on treatment optimization and novel therapeutic approaches.

  • Multiple Sclerosis Management
  • Rheumatoid Arthritis Treatments
  • Crohn's Disease Interventions

Research includes de-escalation strategies and combination therapy evaluations.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.